Mylan Gets License To Sell Generic of Novartis's Vivelle-Dot Menopause Drug

Printer-friendly version
Tags: 
By: 
The Wall Street Journal

Mylan Inc. (MYL) will receive a license to sell generic versions of Vivelle-Dot, a treatment for menopause symptoms, after settling a patent litigation lawsuit with Novartis AG's (NVS) Novartis Pharmaceuticals Corp. affiliate.

Pursuant to the agreement, pending litigation will be dismissed and Mylan will receive a license to begin selling generic versions of the product on Dec. 16, 2013, or earlier under certain circumstances.

Further details of the settlement are confidential.

Mylan confirmed in March that the makers of Vivelle-Dot were challenging its application to market a generic version of the drug.

Vivelle-Dot pulled in about $215 million in sales last year, according to IMS Health. Mylan said it believes it was the first company to file a complete abbreviated application for the drug and can qualify for marketing exclusivity within 180 days upon regulatory approval.

Click HERE to read this article in full.

Resources

BHI Online houses an archive of hormone-related citations for biomedical literature. Also provided are links to PubMed and the NCBI molecular biology resources.
Read more...

Webinars

BHI Online strives to support healthcare professionals through webinars presented by leading experts in their respective fields.
Read more...

Forums

Join the conversation with BHI Online's forums aimed at providing information through communities.
Read more...

Latest News

A selection of stories and articles making headlines in the field of Bioidentical Hormone therapies.
Read more...

Get In Touch

Locate a BHRT doctor, submit an article or just say hello, we'd love to meet you.
Read more...

Sub Page: Side Block 1

Sub Page: Side Block 2

Sub Page: Side Block 3

Sub Page: Side Block 4